ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1706

HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease

Joice Belem 1, Ana Maria Fraga 2, Luís Eduardo Coelho Andrade 1 and Alexandre Wagner de Souza1, 1UNIFESP-EPM, São Paulo, Sao Paulo, Brazil, 2Fleury Group, São Paulo, Sao Paulo, Brazil

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Behcet's syndrome, human leukocyte antigens (HLA) and Genetic Biomarkers

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: HLA-B*51 is considered the genetic marker mostly associated with Behçet’s disease (BD), mainly in countries of the silk route, where its prevalence ranges from 40-80% in individuals with BD. To date, the frequency of HLA-B*51 and its subtypes in Brazilian patients with BD and their associations with clinical manifestations of the disease are not known. The aims of this study are to evaluate the prevalence of HLA-B*51, B*51:01 and HLA-B*51:08 in Brazilian patients with BD and in healthy controls, to evaluate associations between HLA-B*51 and its subtypes and a higher risk for BD in the Brazilian population and to evaluate associations with specific clinical manifestations BD.

Methods: We carried out a cross-sectional study with BD patients and healthy controls. The presence of HLA-B*51 was investigated by sequence-specific polymerase chain reaction (PCR-SSP) and HLA-B*51 positive samples were submitted to genetic sequencing by the Sanger method to evaluate their alleles at medium resolution.

Results: Eighty-three BD patients and 258 healthy controls were evaluated. The prevalence of HLA-B*51 was 30.1% in DB patients and 15.5% in control subjects (p = 0.003). The most frequent alleles among DB patients were HLA-*51:01 (18.1%), HLA-B*51:08 (6.0%), HLA-B*51:22 (2.4%), HLA-B*51:29 (2.4%) and HLA-B*51:02 (2.1%), while HLA-B*51:01 (12.0%) and HLA-B*51:55 (1.2%) were the most frequent subtypes in the control group. Each of the other HLA-B*51 subtypes were observed in less than 1% of the control group. As for clinical manifestations, HLA-B*51 was less frequent in BD patients with neurological involvement (8.0% vs. 29.3%; p = 0.034) while HLA-B*51:01 was more frequently observed in BD patients with ocular involvement (93.3% vs. 60.3%; p = 0.014) and no BD patient with neurological involvement or vascular involvement had HLA-B*51:01. HLA-B*51:08 was more frequent in patients with vascular involvement (60.0% vs. 15.4%; p = 0.012). In the multivariate analysis, the presence of HLA-B*51 was an independent risk factor for BD (OR = 2.410; 95%CI: 1.332-4.361; p = 0.004) and HLA-B*51:08 had an independent association with the development of vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 – 142.115; p = 0.019). No independent associations were observed between HLA-B*51 or with HLA-B*51:01 and disease manifestations of BD.

Conclusion: HLA-B*51 is more frequent in Brazilian BD patients compared to healthy controls and it is an independent risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD.


Disclosure: J. Belem, None; A. Fraga, None; L. Andrade, None; A. de Souza, None.

To cite this abstract in AMA style:

Belem J, Fraga A, Andrade L, de Souza A. HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/hla-b51-and-its-subtypes-in-brazilian-patients-with-behcets-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-b51-and-its-subtypes-in-brazilian-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology